MARKET

MRUS

MRUS

Merus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.65
-0.49
-3.47%
Closed 17:19 05/29 EDT
OPEN
13.99
PREV CLOSE
14.14
HIGH
14.35
LOW
13.32
VOLUME
492.83K
TURNOVER
--
52 WEEK HIGH
20.95
52 WEEK LOW
10.19
MARKET CAP
395.89M
P/E (TTM)
-5.3616
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MRUS stock price target is 21.77 with a high estimate of 35.44 and a low estimate of 16.20.

EPS

MRUS News

More
Merus (MRUS) Investor Presentation - Slideshow
Seeking Alpha - Article · 2d ago
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 2d ago
70 Biggest Movers From Yesterday
Gainers Greenpro Capital Corp. (NASDAQ: GRNQ) shares surged 212.5% to close at $2.58 on Wednesday after jumping over 33% on Tuesday.
Benzinga · 3d ago
58 Stocks Moving In Wednesday's Mid-Day Session
Gainers Hertz Global Holdings, Inc. (NYSE: HTZ) shares jumped 127% to $1.26. Hertz Global shares dipped over 80% on Tuesday after the company filed for Chapter 11 bankruptcy protection.
Benzinga · 4d ago
Benzinga's Top Upgrades, Downgrades For May 27, 2020
Upgrades
Benzinga · 4d ago
RBC Capital Downgrades Merus to Sector Perform, Lowers Price Target of $16
RBC Capital analyst Brian Abrahams downgrades Merus (NASDAQ:MRUS) from Outperform to Sector Perform and lowers the price target from $21 to $16.
Benzinga · 4d ago
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Benzinga · 05/24 18:40
Guggenheim Maintains Buy on Merus, Lowers Price Target to $23
Guggenheim maintains Merus (NASDAQ:MRUS) with a Buy and lowers the price target from $26 to $23.
Benzinga · 05/18 14:38

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About MRUS

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
More

Webull offers kinds of Merus NV stock information, including NASDAQ:MRUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRUS stock news, and many more online research tools to help you make informed decisions.